{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,3,27]],"date-time":"2025-03-27T12:00:01Z","timestamp":1743076801002,"version":"3.40.3"},"reference-count":40,"publisher":"Elsevier","isbn-type":[{"type":"print","value":"9780443293245"}],"license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000001","name":"National Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000001","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024]]},"DOI":"10.1016\/bs.apha.2024.05.002","type":"book-chapter","created":{"date-parts":[[2024,7,12]],"date-time":"2024-07-12T21:32:02Z","timestamp":1720819922000},"page":"1-38","source":"Crossref","is-referenced-by-count":0,"title":["Making new drugs the hard way"],"prefix":"10.1016","author":[{"given":"Dennis","family":"Liotta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/bs.apha.2024.05.002_bib1","unstructured":"Adams, P. (2021) In the race for a Covid-19 pill, a little lab plays a big role. The New York Times."},{"issue":"6B","key":"10.1016\/bs.apha.2024.05.002_bib2","doi-asserted-by":"crossref","first-page":"16S","DOI":"10.1016\/S0002-9343(99)00375-7","article-title":"Discovery of non-A, non-B hepatitis and identification of its etiology","volume":"107","author":"Alter","year":"1999","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/bs.apha.2024.05.002_bib3","first-page":"1631","article-title":"Replication of hepatitis C virus","volume":"81","author":"Bartenschlager","year":"2000","journal-title":"The Journal of General Virology"},{"key":"10.1016\/bs.apha.2024.05.002_bib4","unstructured":"Belleau, B., Dixit, D., Nguyen, N., & Krauss, J.-L. (1989). Design and activity of a novel class of nucleoside analogues effective against HIV-1. Abstr. 5th Int Conf. AIDS, 515."},{"issue":"21","key":"10.1016\/bs.apha.2024.05.002_bib18","first-page":"689","article-title":"HIV surveillance \u2013 United States\u00a01981\u20132008","volume":"60","year":"2011","journal-title":"Morbidity and Mortality Weekly Report (MMWR)"},{"key":"10.1016\/bs.apha.2024.05.002_bib5","doi-asserted-by":"crossref","first-page":"9377","DOI":"10.1021\/ja00024a058","article-title":"In situ complexation directs the stereochemistry of N-glycosylation in the synthesis of thialanyl and dioxolanyl nucleoside analogs","volume":"113","author":"Choi","year":"1991","journal-title":"Journal of the American Chemical Society"},{"key":"10.1016\/bs.apha.2024.05.002_bib6","doi-asserted-by":"crossref","first-page":"6503","DOI":"10.1021\/jo00023a010","article-title":"Enantiomeric synthesis of (+)-BCH-189 [(+)-(2S,5R)-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine] from D-mannose and its anti-HIV activity","volume":"56","author":"Chu","year":"1991","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/bs.apha.2024.05.002_bib7","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1128\/AAC.36.1.202","article-title":"The separated enantiomers of 2\u2032-deoxy-3\u2032-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro","volume":"36","author":"Coates","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"1","key":"10.1016\/bs.apha.2024.05.002_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41564-020-00835-2","article-title":"Therapeutically administered ribonucleoside analog MK-4482\/EIDD-2801 blocks SARS-CoV-2 transmission in ferrets","volume":"6","author":"Cox","year":"2021","journal-title":"Nature Microbiology"},{"key":"10.1016\/bs.apha.2024.05.002_bib9","doi-asserted-by":"crossref","first-page":"8495","DOI":"10.1073\/pnas.88.19.8495","article-title":"Inhibition of the replication of hepatitis B virus in vitro by 2\u2032,3\u2032-dideoxy-3\u2032-thiacytidine and related analogues.","volume":"88","author":"Doong","year":"1991","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"8","key":"10.1016\/bs.apha.2024.05.002_bib10","first-page":"595","article-title":"The role of academic institutions in the development of drugs","volume":"18","author":"Edwards","year":"2019","journal-title":"Nature Reviews\u00a0Drug Discovery"},{"issue":"10","key":"10.1016\/bs.apha.2024.05.002_bib11","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1007\/BF00623322","article-title":"Self-organization of matter and the evolution of biological macromolecules.","volume":"58","author":"Eigen","year":"1971","journal-title":"Die Naturwissenschaften"},{"key":"10.1016\/bs.apha.2024.05.002_bib12","unstructured":"Emergency Use Authorization. (2021). Fact sheet for healthcare workers. US Food and Drug Administration."},{"key":"10.1016\/bs.apha.2024.05.002_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/bs.enz.2021.06.003","article-title":"HCV RdRp, sofosbuvir and beyond","volume":"49","author":"Feng","year":"2021","journal-title":"Enzyme"},{"key":"10.1016\/bs.apha.2024.05.002_bib14","doi-asserted-by":"crossref","first-page":"S237","DOI":"10.1002\/hep.1840360730","article-title":"Side effects of therapy of hepatitis C and their management.","volume":"36","author":"Fried","year":"2002","journal-title":"Hepatology (Baltimore, Md.)"},{"key":"10.1016\/bs.apha.2024.05.002_bib15","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1128\/AAC.36.12.2686","article-title":"The anti-hepatitis B virus activities, cytotoxicities, and anabolic profiles of the (-) and (+) enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine","volume":"36","author":"Furman","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/bs.apha.2024.05.002_bib16","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1177\/095632029500600601","article-title":"The effect of absolute configuration on anti-HIV and anti-HBV activity of nucleoside analogues","volume":"6","author":"Furman","year":"1995","journal-title":"Antiviral Chemistry & Chemotherapy"},{"issue":"5","key":"10.1016\/bs.apha.2024.05.002_bib17","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1128\/AAC.06108-11","article-title":"Preclinical evaluation of the HIV-1 fusion inhibitor L'644 as a potential candidate microbicide","volume":"56","author":"Harman","year":"2012","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"5","key":"10.1016\/bs.apha.2024.05.002_bib19","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.jhep.2009.08.004","article-title":"The long and winding road leading to the identification of the hepatitis C virus","volume":"51","author":"Houghton","year":"2009","journal-title":"Journal of Hepatology"},{"issue":"21","key":"10.1016\/bs.apha.2024.05.002_bib39","doi-asserted-by":"crossref","first-page":"5563","DOI":"10.1021\/jo00047a004","article-title":"Enzyme-Mediated Enantioselective Preparation of Pure Enantiomers of the Antiviral Agent 2\u2032,3\u2032-Dideoxy-5-Fluoro-3\u2032-Thiacytidine (FTC) and Related Compounds","volume":"57","author":"Hoong","year":"1992","journal-title":"J. Org. Chem"},{"key":"10.1016\/bs.apha.2024.05.002_bib20","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41587-021-00843-5","article-title":"Life sciences intellectual property licensing at the Massachusetts Institute of Technology","volume":"39","author":"Huang","year":"2021","journal-title":"Nature Biotechnology"},{"key":"10.1016\/bs.apha.2024.05.002_bib37","unstructured":"Idenix Pharmaceuticals LLC v. Gilead Sciences Inc., 941 F.3d 1149 (Fed. Cir. 2019)."},{"issue":"5","key":"10.1016\/bs.apha.2024.05.002_bib38","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1021\/acsmedchemlett.8b00124","article-title":"Academic Drug Development: The DRIVE Model","volume":"9","author":"Liotta","year":"2018","journal-title":"ACS Medicinal Chemistry Letters"},{"issue":"1","key":"10.1016\/bs.apha.2024.05.002_bib21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/088922200309539","article-title":"Perspective \u2013 Lethal mutagenesis of HIV by mutagenic ribonucleotide analogs","volume":"16","author":"Loeb","year":"2000","journal-title":"AIDS Research and Human Retroviruses"},{"key":"10.1016\/bs.apha.2024.05.002_bib22","doi-asserted-by":"crossref","first-page":"8416","DOI":"10.1128\/jvi.71.11.8416-8428.1997","article-title":"Biochemical properties of hepatitis C virus NS5B RNA-dependent RNA polymerase and identification of amino acid sequence motifs essential for enzymatic activity","author":"Lohmann","year":"1997","journal-title":"Journal of Virology"},{"key":"10.1016\/bs.apha.2024.05.002_bib23","article-title":"Where drugs come from: The numbers","author":"Lowe","year":"2010","journal-title":"Science Translational Medicine"},{"key":"10.1016\/bs.apha.2024.05.002_bib24","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1128\/AAC.37.10.2206","article-title":"Infectious amplification of wild-type human-immunodeficiency-virus from patients lymphocytes and modulation by reverse-transcriptase inhibitors in-vitro","volume":"37","author":"Mathez","year":"1993","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"7","key":"10.1016\/bs.apha.2024.05.002_bib25","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1021\/jo9717898","article-title":"A completely diastereoselective electrophilic fluorination of a chiral, noncarbohydrate sugar ring precursor: Application to the synthesis of several novel 2\u2019-fluoronucleosides","volume":"63","author":"McAtee","year":"1998","journal-title":"The Journal of Organic Chemistry"},{"key":"10.1016\/bs.apha.2024.05.002_bib26","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/978-3-642-20718-1_14","article-title":"Viruses with single-stranded, positive-sense RNA genomes","author":"Modrow","year":"2013","journal-title":"Molecular Virology"},{"issue":"9","key":"10.1016\/bs.apha.2024.05.002_bib27","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/nar\/26.9.2105","article-title":"Synthesis and RNA polymerase incorporation of the degenerate ribonucleotide analogue rPTP","volume":"26","author":"Moriyama","year":"1998","journal-title":"Nucleic Acids Research"},{"issue":"10080","key":"10.1016\/bs.apha.2024.05.002_bib28","first-page":"1779","article-title":"Academic drug discovery centres: A new model for innovation","volume":"389","author":"Mullard","year":"2017","journal-title":"The Lancet"},{"key":"10.1016\/bs.apha.2024.05.002_bib29","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1128\/AAC.36.3.672","article-title":"Activities of the four optical isomers of 2\u2019,3\u2019-dideoxy-3\u2019-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"key":"10.1016\/bs.apha.2024.05.002_bib30","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1128\/AAC.36.11.2423","article-title":"Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine","volume":"36","author":"Schinazi","year":"1992","journal-title":"Antimicrobial Agents and Chemotherapy"},{"issue":"6","key":"10.1016\/bs.apha.2024.05.002_bib31","first-page":"471","article-title":"Challenges and opportunities in academic drug discovery","volume":"6","author":"Schreiber","year":"2010","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/bs.apha.2024.05.002_bib32","doi-asserted-by":"crossref","first-page":"7202","DOI":"10.1021\/jm100863x","article-title":"Discovery of a beta-D-2\u2032-deoxy-2\u2032-alpha- fluoro-2\u2032-beta-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus","volume":"53","author":"Sofia","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"issue":"10049","key":"10.1016\/bs.apha.2024.05.002_bib33","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/S0140-6736(16)30579-7","article-title":"The global burden of viral hepatitis from 1990 to 2013: Findings from the Global Burden of Disease Study 2013","volume":"388","author":"Stanaway","year":"2016","journal-title":"The Lancet"},{"key":"10.1016\/bs.apha.2024.05.002_bib34","doi-asserted-by":"crossref","first-page":"5653","DOI":"10.1073\/pnas.90.12.5653","article-title":"Rapid in vitro selection of human-immunodeficiency-virus type-1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse-transcriptase","volume":"90","author":"Tisdale","year":"1993","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.apha.2024.05.002_bib55","unstructured":"University of Minnesota v. Gilead Sciences, 61 F.4th 1350 (Fed. Cir. 2023)."},{"issue":"1","key":"10.1016\/bs.apha.2024.05.002_bib35","doi-asserted-by":"crossref","DOI":"10.1093\/ve\/vex003","article-title":"In vivo mutation rates and the landscape of fitness costs of HIV-1","volume":"3","author":"Zanini","year":"2017","journal-title":"Virus Evolution"},{"issue":"10","key":"10.1016\/bs.apha.2024.05.002_bib36","first-page":"802","article-title":"Innovative models for academic-industrial partnerships in drug discovery","volume":"37","author":"Zerhouni","year":"2016","journal-title":"Trends in Pharmacological Sciences"}],"container-title":["Advances in Pharmacology","The Discovery of New Medicines in Academia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000176?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1054358924000176?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,24]],"date-time":"2024-11-24T01:20:20Z","timestamp":1732411220000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1054358924000176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"ISBN":["9780443293245"],"references-count":40,"URL":"https:\/\/doi.org\/10.1016\/bs.apha.2024.05.002","relation":{},"ISSN":["1054-3589"],"issn-type":[{"type":"print","value":"1054-3589"}],"subject":[],"published":{"date-parts":[[2024]]}}}